Dyne Net Loss Widens to $193.6 Million in Q3 as Spending Rises
Dyne Therapeutics reported a third-quarter 2026 net loss of $193.6 million, or $1.06 per share, up from $108.0 million, or $0.76 per share, a year earlier. The increase reflects higher research and development and general and administrative costs as the company prepares for a possible U.S. launch of z-rostudirsen, and the filing reports $1.134 billion in cash and marketable securities.
Key points
- Q3 2026 net loss was $193.6 million, or $1.06 per share, compared with $108.0 million, or $0.76 per share, in Q3 2025.
- R&D expenses rose to $161.7 million from $97.2 million, driven by manufacturing for z-rostudirsen and Phase 3 trial costs.
- G&A expenses rose to $35.3 million from $16.7 million, mainly for launch preparation and higher headcount.
- Cash, cash equivalents and marketable securities were $1.134 billion at September 30, 2026, which the company says will fund operations into Q2 2028.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.